Аннотация:
A multicenter prospective comparative randomized study was carried out to evaluate the efficiency and safety of Pabal® (carbetocin) and oxitocin, used for prevention of the postpartum hemorrhages in abdominal delivery. The volume of blood loss in patients treated by Pabal (n=163) and oxitocin (n=180) were compared in the patients with uterine cicatrix, large fetus, in cesarean section combined with conservative myomectomy, in twin pregnancy, placental presentation, and preterm detachment of normally located placenta. Pabal proved to be highly effective and safe; blood loss was significantly lower in response to Pabal in comparison with preventive oxitocin.
Belomestnov S.R.
Galina T.V.
Zhilin A.V.
Kirbasova N.P.
Kozyrenko E.M.
Kulikov A.V.
Radzinsky V.E.
Rymashevsky A.N.
Kholopov A.V.
Shifman E.M.
Tskhay V.B.
Regional Children’s Hospital № 1
Peoples’ Friendship University of Russia
City Hospital № 29 named after N.E. Bauman
Первый МГМУ им. И.М. Сеченова МЗ РФ
I.M. Sechenov First Moscow State Medical University
Regional Perinatal Center
«Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации
Ural State Medical University
«Ростовский государственный медицинский университет»
Rostov State Medical University
Maternity Hospital № 5
Department of Health Care of Tomsk Region
Moscow Regional Research and Clinical Institute named after M.F. Vladimirsky
Красноярский государственный медицинский университет
Krasnoyarsk State Medical University
Krasnoyarsk Regional Clinical Center for Maternal and Child Welfare
Summing up a multicenter prospective comparative randomized study of the efficiency and safety of Pabal® (carbetocin) and oxytocin
Текст визуальный электронный
Архив акушерства и гинекологии им. В.Ф. Снегирева
Eco-Vector
Т. 2, № 1 С. 48-54
2015
Пабал
Pabal
карбетоцин
carbetocin
профилактика послеродовых кровотечений
prevention of postpartum bleeding
многоцентровое исследование
multicenter study
Статья
A multicenter prospective comparative randomized study was carried out to evaluate the efficiency and safety of Pabal® (carbetocin) and oxitocin, used for prevention of the postpartum hemorrhages in abdominal delivery. The volume of blood loss in patients treated by Pabal (n=163) and oxitocin (n=180) were compared in the patients with uterine cicatrix, large fetus, in cesarean section combined with conservative myomectomy, in twin pregnancy, placental presentation, and preterm detachment of normally located placenta. Pabal proved to be highly effective and safe; blood loss was significantly lower in response to Pabal in comparison with preventive oxitocin.